Delcath Systems Inc
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Delcath Systems' stock, with a target price of $22.63 indicating strong potential.
Financial Health
Delcath Systems is generating moderate revenue and cash flow, with strong profit margins but limited earnings.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring DCTH
Next-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: July 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Targeted Oncology Approach
Delcath’s hepatic delivery tech concentrates chemotherapy in the liver, which could improve local control — though clinical and regulatory outcomes remain uncertain.
Clinical & Regulatory Focus
Trial results and approvals are key value drivers; setbacks or delays can materially affect the share price, so monitor updates closely.
Commercial & Financing Risks
Small market cap means growth depends on adoption, reimbursement and access to capital; funding needs can dilute existing holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
